Hemiparesis After Stroke, Traumatic Brain Injury
Conditions
Keywords
Muscle spasticity, Botulinum toxin
Brief summary
The most common motor deficiency after stroke or traumatic brain injury is hemiparesis. Most hemiparetic patients recover walking, but rarely with a speed permitting easy ambulation outdoors with family or friends. One of the mechanisms of gait impairment in hemiparesis is insufficient active hip flexion during swing phase, which leads to insufficient ground clearing at swing phase, with associated gait slowness and risks of fall. The main hypothesis behind the present study is that insufficient hip flexion during hemiparetic gait is partly due to overactivity of rectus femoris. Focal treatment of lower limb muscle overactivity using botulinum toxin has not been demonstrated to increase walking speed in hemiparesis as yet. However, most studies have focused distally, on improving foot dorsiflexion only. The purpose of this study is to compare the effects of botulinum toxin injection and placebo in rectus femoris (RF) + plantar flexors versus plantar flexors only.
Detailed description
Randomized, double blind, parallel-group study in chronic, non-evolutive brain damaged patients (\>6 months since stroke or brain trauma) and ambulating at \<1.3 m/sec at maximal speed barefoot (AT10) Group 1: 150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment. Group 2: 150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment. Group 3: 150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.
Interventions
DRUGPlacebo injection
Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus. 150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment
Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus. 150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.
DRUGPlacebo injection and botulinum toxin injection
Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.. 150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment.
Sponsors
Merz Pharmaceuticals GmbH
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hemiparesis from stroke, brain trauma, or non evolutive brain tumor \>6 months before enrolment * Hip flexion at swing phase on the paretic side clinically insufficient (rated \<15° by the clinical investigator) * Passive ankle dorsiflexion clinically insufficient at late stance (rated \<90° by the clinical investigator) * Maximal ambulation speed barefoot over 10 metres \< 1,3 m/sec * Age ≥ 18 * Signed consent form
Exclusion criteria
* Ambulation impossible barefoot * Passive hip flexion amplitude (with the knee flexed) \< 45° on paretic side * Severe intercurrent disease ou cognitive dysfunction making effective communication or study participation impossible. * Current anticoagulation with INR\> 3,5 ; less than 15 days prior to D1 * Pregnancy, lactation, or premenopause woman not taking contraception * Hypersensitivity to botulinum toxin or its excipients, myasthenia gravis, Lambert-Eaton syndrome, concomitant aminoside treatment. * Infection or inflammation at injection sites. * Injection in lower limb less than 3 months prior to D1 * Person not covered by social security
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in maximum speed of barefoot ambulation without technical assistance over 10 meters, between the pre-injection visit (D1) and 3 weeks (D21) post injection | Preinjection visit (D1) and 3 weeks post injection (D21) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Step cadence at comfortable and maximal speed, barefoot and with shoes over 10 meters | Day 1 and Day 21 | — |
| Physiological Cost Index (PCI) over a walking test of 2 minutes at maximal speed with shoes | Day 1 and Day 21 | — |
| Potential AEs of injections (pain or discomfort during the injection or post injection, or ecchymoses at insertion site) and potential AEs related to the injected drug (muscle weakening, allergies) | Day 1, Day 21, Day 60 | — |
| Change ambulation speed at comfortable and maximal speed, barefoot and with shoes over 10 meters | Day 1 and Day 21 | — |
| Maximal amplitude and speed of active hip flexion and passive knee flexion during swing phase, measured in gait kinematic recording, at comfortable and maximal speed | Day 1 and Day 21 | — |
| Maximal amplitude and speed of passive ankle dorsiflexion at late stance phase, measured in gait kinematic recording, at comfortable and maximal speed | Day 1 and Day 21 | — |
| Maximal voluntary isometric EMG (MVIE) of rectus femoris and soleus, measured by surface EMG, in an isometric position with hip at 15° flexion, knee at 30° flexion, and ankle at 80° of dorsiflexion | Day 1 and Day 21 | calculating the mean rectified voltage over 100 ms around the peak of rectified EMG on each of these muscles |
| Step length at comfortable and maximal speed, barefoot and with shoes over 10 meters | Day 1 and Day 21 | — |
| Cocontraction indices of rectus femoris and soleus during the first half of swing phase, calculating the ratio MRVSP/MVIE for each of these muscles. | Day 1 and Day 21 | — |
| Mean rectified voltage of soleus during the first half of stance phase (MRVSP), from heel-on to maximal knee extension, measured by surface EMG (electrodes 2 cm apart) immediately after MVIE measure. | Day 1 and Day 21 | — |
| Inappropriate Contraction Indices of soleus during the first half of stance phase, calculating the ratio MRVSP / MVIE | Day 1 and Day 21 | — |
| Spasticity Angle et grade of rectus femoris and soleus (Five Step Assessment) | Day 1, Day 21, Day 60 | — |
| Weakness Angle of rectus femoris and soleus (Five Step Assessment) | Day 1, Day 21, Day 60 | — |
| Quality of life measured by EQ5D | Day 1, Day 60 | — |
| Mean weekly number of steps | Between Day-15 and Day1, Day7 and Day21 and between Day45 and Day60 | — |
| Mean rectified voltage of rectus femoris and soleus during the first half of swing phase (MRVSP), from toe-off to maximal hip flexion, measured by surface EMG (electrodes 2 cm apart) immediately after MVIE measure. | Day 1 and Day 21 | — |
Countries
France
Contacts
Primary ContactJean-Michel GRACIES, MD, PhD
Outcome results
None listed